CervoMed Inc. Files 8-K on Financials
Ticker: CRVO · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
CervoMed filed its 8-K, updating investors on financial results.
AI Summary
CervoMed Inc. filed an 8-K on August 11, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits, with the report period and date as of change both being August 11, 2025. The company, formerly known as Diffusion Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This 8-K filing provides an update on CervoMed Inc.'s financial condition and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- CervoMed Inc. (company) — Registrant
- Diffusion Pharmaceuticals Inc. (company) — Former company name
- 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (location) — Principal executive address
- August 11, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing by CervoMed Inc.?
The primary purpose of this 8-K filing is to report on CervoMed Inc.'s Results of Operations and Financial Condition, and it includes financial statements and exhibits.
When was this 8-K report filed and what is the date as of which the information is reported?
This 8-K report was filed on August 11, 2025, and the date as of which the information is reported is also August 11, 2025.
What was CervoMed Inc. formerly known as?
CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc.
In which state is CervoMed Inc. incorporated and what is its principal executive address?
CervoMed Inc. is incorporated in Delaware and its principal executive address is 20 Park Plaza, Suite 424, Boston, Massachusetts 02116.
What is the SIC code for CervoMed Inc.?
The Standard Industrial Classification (SIC) code for CervoMed Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-08-11 08:14:32
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20250808_8k.htm (8-K) — 29KB
- ex_850337.htm (EX-99.1) — 118KB
- logosmlr.jpg (GRAPHIC) — 4KB
- 0001437749-25-025814.txt ( ) — 293KB
- crvo-20250811.xsd (EX-101.SCH) — 3KB
- crvo-20250811_def.xml (EX-101.DEF) — 11KB
- crvo-20250811_lab.xml (EX-101.LAB) — 15KB
- crvo-20250811_pre.xml (EX-101.PRE) — 11KB
- crvo20250808_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On August 11, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended June 30, 2025. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued August 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 11, 2025 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer, General Counsel & Secretary 3